Be Aware of New Safety Issues With Xeljanz

Safety concerns are stacking up with tofacitinib (Xeljanz, Xeljanz XR) for rheumatoid arthritis and other autoimmune diseases.

Xeljanz and other "Janus kinase (JAK) inhibitors" are already linked to blood clots...serious infections...and other issues.

Now experts are warning that Xeljanz may increase the risk of heart attacks and other serious cardiovascular (CV) events. There are also more data that it increases the risk of cancer.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote